Imatinib mesylate may induce long-term clinical response in FIP1L1-PDGFRα-negative hypereosinophilic syndrome. (Q54618199)

1 June 2018

title

Imatinib mesylate may induce long-term clinical response in FIP1L1-PDGFRα-negative hypereosinophilic syndrome. (English)

1 reference

1 June 2018

1 reference

1

Grzegorz Helbig

1 reference

1 June 2018

2

Marek Hus

1 reference

1 June 2018

Slawomira Kyrcz-Krzemien

8

object named as

Sławomira Kyrcz-Krzemień

1 reference

1 June 2018

author name string

Magdalena Hałasz

3

1 reference

1 June 2018

Marek Dudziński

4

1 reference

1 June 2018

Agnieszka Więcławek

5

1 reference

1 June 2018

Małgorzata Stachowicz

6

1 reference

1 June 2018

Anna Soja

7

1 reference

1 June 2018

publication date

22 January 2011

1 reference

1 June 2018

published in

Medical Oncology

1 reference

1 June 2018

volume

29

1 reference

1 June 2018

issue

2

1 reference

1 June 2018

page(s)

1073-1076

1 reference

1 June 2018

https://scigraph.springernature.com/pub.10.1007/s12032-011-9831-1

exact match

0 references

cites work

The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9831-1

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9831-1

The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9831-1

Success of short-term, higher-dose imatinib mesylate to induce clinical response in FIP1L1-PDGFRalpha-negative hypereosinophilic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9831-1

T-cell abnormalities are present at high frequencies in patients with hypereosinophilic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9831-1

A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRA-expressing patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9831-1

Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9831-1

Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRalpha mutation status

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9831-1

A short low-dose imatinib trial allows rapid identification of responsive patients in hypereosinophilic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9831-1

Two novel imatinib-responsive PDGFRA fusion genes in chronic eosinophilic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-9831-1

The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21258876

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

How I treat hypereosinophilic syndromes

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21258876

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S12032-011-9831-1

1 reference

1 June 2018

1 reference

1 June 2018